Meeting
2019 Breakthrough
Identification of sentinel lymph nodes using contrast-enhanced ultrasound in breast cancer patients who underwent neoadjuvant chemotherapy.
Authors
Xiufeng Wu
Fujian Provincial Cancer Hospital, Fuzhou, China
Xiufeng Wu , Lina Tang , Yi Zeng , Xia Chen
Organizations
Fujian Provincial Cancer Hospital, Fuzhou, China, Fujian Cancer Hospital, Fuzhou, China, Fuajian Provincial Cancer Hospital, Fuzhou, China
Research Funding
No funding received
None.
Background: The aim of this prospective study was to evaluate the feasibility of contrast-enhanced ultrasonography (CEUS) for the identification of sentinel lymph node (SLN) in breast cancer patients with cN0 following neoadjuvant chemotherapy (NAC). Methods: Patients with cN0 following NAC (n=66) received a periareolar injection of SonoVue followed by ultrasound (US) to identify contrast-enhanced SLN before surgery. All patients underwent axillary lymph node dissection for verification of axillary node status after the SLN biopsy. The identification rate, sensitivity, specificity, accuracy, false negative rate, negative predictive value, positive predictive value was recorded. Results: In almost all cases, the SLNs were easily identified with an identification rate of 98.5 % (65/66). Compared with pathological diagnosis, sensitivity, specificity, accuracy, and false negative rate of CEUS for SLN diagnosis were 66.7%, 95.8%, 78.8%, and 14.3% respectively. Conclusions: Identification of SLN by CEUS is a technically feasible method with an identification rate as high as 98.5%.
| Characteristics | Number of patients (N=66) (%) |
|---|---|
| Age | |
| <50 | 43(65.2%) |
| >50 | 23(34.8%) |
| Tumor size | |
| <2cm | 18(27.3%) |
| >2cm | 45(68.2%) |
| Tx | 3 (4.5%) |
| Grade | |
| I | 10(15.2%) |
| II | 22(33.3%) |
| III | 34(51.5%) |
| Tumor histology | |
| IDC | 50(75.8%) |
| ILC | 16(24.2%) |
| Estrogen receptor status | |
| Positive | 16(24.2%) |
| Negative | 50(75.8%) |
| HER2 status | |
| Positive | 42(63.6%) |
| Negative | 24(36.4%) |
| SLN status using CEUS | |||||
|---|---|---|---|---|---|
| ALND | Total | ||||
| Positive | Negative | ||||
| Positive | 12 | 2 | 14 | PPV=85.7% (12/14) | |
| Negative | 6 | 46 | 52 | NPV=88.5% (45/52) | |
| Total | 18 | 48 | 66 | FNR=14.3% (2/14) | |
| Sens=66.7% (12/18) | Spec=95.8% (46/48) | Accuracy=78.8%(52/66) | |||
Sens: Sensitivity; Spec: Specificity; PPV: Positive predictive value; NPV: Negative predictive value. FNR: False negative rate.
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Abstract Details
Session Type
Poster Session
Session Title
Poster Session A: Access to Care, Diagnostics, Early Detection and Diagnosis, Prevention and Screening, and Surveillance
Track
Access to Care,Diagnostics,Early Detection and Diagnosis,Prevention and Screening,Surveillance
Sub Track
Early Detection and Diagnosis
Citation
J Glob Oncol 5, 2019 (suppl 1; abstr 59)
DOI
10.1200/JGO.2019.5.suppl.59
Abstract #
59
Poster Bd #
D13
Abstract Disclosures
Similar Abstracts
Abstract
2023 ASCO Annual Meeting
The proliferation biomarker SPAG5 expression in HER2 low and HER2 overexpression early breast cancer (BC) predicting tumour response to neoadjuvant chemotherapy (NACT) with and without trastuzumab.
First Author: Tarek Mohamed Ahmed Abdel-Fatah
Abstract
2023 ASCO Annual Meeting
Longitudinal MRI-based fusion novel model to predict pathological complete response in breast cancer treated with neoadjuvant chemotherapy: A multicenter, retrospective study.
First Author: Kun Wang
Abstract
2023 ASCO Annual Meeting
Moderate physical exercise and immune system modulation in patients with breast cancer treated with neoadjuvant chemotherapy.
First Author: Ornella Garrone
Abstract
2024 ASCO Annual Meeting
Evaluation of early response in association with pathological response in patients with breast cancer receiving neoadjuvant chemotherapy.
First Author: Yongjiu Wang